Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
HOT-7
HOT-7 is a psychedelic phenethylamine of the 2C and HOT-x families, specifically the N-hydroxy derivative of 2C-T-7, and is described as a prodrug for it. Alexander Shulgin first documented it in his 1991 book PiHKAL, noting that its effects are nearly identical to those of 2C-T-7, sharing a similar dose range while perhaps being slightly shorter in duration. It is taken orally and remains rarely encountered.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
The dose-response curve for this substance is considered atypical, warranting particular caution when determining dosage. There is speculation that HOT-7 may exhibit monoamine oxidase inhibitor (MAOI) activity, similar to what has been suggested for 2C-T-7.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
HOT-7 produces a distinctly psychedelic state that is reported as closely resembling that of 2C-T-7, for which it may act as a prodrug. The transition into effects can be somewhat difficult, accompanied by a faint sensation in the stomach, but by the second hour the experience becomes clearly psychedelic and the body largely recedes from attention. The state is described as very rich in closed-eye imagery while open-eye visuals remain comparatively modest, and it lends itself well to interpretive and conceptual thinking. Reports note an undercurrent of sadness threaded through an otherwise very positive experience, and the dose curve has been described as abnormal.
Physical
Both mental and physical stimulation are reported, along with restlessness, muscle tension, sweating and chills, and difficulty sleeping, though at least one account describes drifting into easy sleep by the seventh hour.
Autonomic
Uncomfortable
Cognitive
The headspace favors interpretive and conceptual thought, with euphoria, empathy, insight, and a softening of ego, though confusion and a persistent thread of sadness have also been reported.
Visual
Eyes-closed imagery is reported as very rich, while eyes-open visuals are described as less prominent than anticipated.
Hallucinatory States
Tactile
Pharmacology
Pharmacodynamics
HOT-7 is the N-hydroxy derivative of 2C-T-7, and its pharmacological action is described as closely paralleling that parent compound. It may function as a prodrug of 2C-T-7, with the general observation that an N-hydroxy amine carries approximately the same potency and the same action as its N-hydrogen counterpart. Whether the N-hydroxy compound is reduced to the N-H material in the body, or the N-H material is instead oxidized to the N-hydroxy material, has been raised as an open question, with the intrinsically active agent unresolved in either direction. MAOI effects have been suggested as possible, by analogy with 2C-T-7, but this remains unconfirmed.
Pharmacokinetics
HOT-7 is taken orally. It may act as a prodrug of 2C-T-7, though the direction of the conversion, reduction of the N-hydroxy group to the N-H amine or oxidation of the N-H amine to the N-hydroxy form, is not established.
Interactions
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Harm Potential
History & Culture
HOT-7 was first described in the scientific literature by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), where he listed it among the N-hydroxy analogues he had explored. Shulgin arrived at the compound while testing a broader hypothesis about the equivalence of…
Legality
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the HOT-7 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.